| Effect of bosentan on plasma markers of endothelial cell activity in patients with secondary pulmonary hypertension related to connective tissue diseases. | |
| | |
MedLine Citation:
|
PMID: 19208592 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVE: To evaluate plasma markers of endothelial cell activity in patients with pulmonary arterial hypertension (PAH) induced by connective tissue diseases (CTD) before and after 3-month administration of bosentan. METHODS: We quantified E, L and P-selectin (sE-S, sL-S, sP-S), thrombomodulin (TM), monocyte-chemotactic protein 1 (MCP-1), human soluble CD40 ligand (sCD40L), and nitric oxide (NO) in 18 patients and 18 controls. We evaluated right ventricular systolic pressure (RVSP) and the 6-minute walk test (6-MWT). RESULTS: All plasma markers but sL-S and TM at Time 0 were significantly higher in patients compared with controls. After 3 months of therapy, decreased levels were noted in NO (Time 0 24.05+/-6.01 mmol/l, Time 1 13.92+/-3.40 mmol/l; p<0.001) and sCD40L (Time 0 1685.33+/-866 pg/ml, Time 1 1055.11+/-630.6 pg/ml; p=0.017). In contrast, sP-S was significantly increased (Time 0 88.36+/-47.76 ng/ml, Time 1 147.21+/-94.43 ng/ml; p=0.021). All patients remained stable in WHO class III, and in 9 patients we noted an improvement in 6-MWT. A correlation was found between Delta of RVSP and 6-MWT (r2=0.5355, p<0.001) as well as between Delta-sP-S and both Delta-6-MWT and Delta-RVSP. An increase sP-S level was found in 89% of nonresponder patients, whereas 55% of responders showed a stable or reduced sP-S level (p=0.016 responder vs nonresponder). CONCLUSION: Treatment with bosentan for 3 months induced a beneficial effect by restoring endothelial function through a decrease in the markers of endothelial cell activity, leading to stabilization or improvement of severe PAH. |
| | |
Authors:
|
Giuseppe Cella; Fabrizio Vianello; Franco Cozzi; Helga Marotta; Francesco Tona; Graziella Saggiorato; Omer Iqbal; Jawed Fareed |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't Date: 2009-01-22 |
Journal Detail:
|
Title: The Journal of rheumatology Volume: 36 ISSN: 0315-162X ISO Abbreviation: J. Rheumatol. Publication Date: 2009 Apr |
Date Detail:
|
Created Date: 2009-04-03 Completed Date: 2009-06-01 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 7501984 Medline TA: J Rheumatol Country: Canada |
Other Details:
|
Languages: eng Pagination: 760-7 Citation Subset: IM |
Affiliation:
|
Department of Medical Sciences, University of Padova Medical Schoo, Via Ospedale Civile 105, 35100 Padova, Italy. giuseppe.cella@unipd.it |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Antihypertensive Agents / therapeutic use* Biological Markers / blood* Connective Tissue Diseases / complications*, physiopathology Disease Progression Endothelial Cells / metabolism* Endothelium, Vascular* / cytology, physiopathology Exercise Test Female Humans Hypertension, Pulmonary / blood*, drug therapy*, etiology*, physiopathology Male Middle Aged Sulfonamides / therapeutic use* Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Antihypertensive Agents; 0/Biological Markers; 0/Sulfonamides; 147536-97-8/bosentan |
| Comments/Corrections | |
Comment In:
|
J Rheumatol. 2009 Apr;36(4):665-6
[PMID:
19342719
]
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: The natural history of disability and its determinants in adults with lower limb musculoskeletal pai...
Next Document: The influence of the 1997 updated classification criteria for systemic lupus erythematosus: epidemio...